The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Tyrosine-kinase Inhibitors in Patients with Metastatic Primary Renal Cell Carcinoma

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2014 Sep 2

PMID 25177235

Citations 19

Authors

Carmelo Caldarella

Barbara Muoio

Maria Antonietta Isgro

Emilio Porfiri

Giorgio Treglia

Luca Giovanella

Affiliations

Soon will be listed here.

Abstract

Background: Positron emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose (FDG) is increasingly used in the evaluation of patients with advanced renal cell carcinoma (RCC), primarily for staging purposes. The aim of this paper is to perform a systematic review about the usefulness of PET-CT using FDG in response assessment after treatment with tyrosine-kinase inhibitors (TKIs) in patients with advanced RCC.

Materials And Methods: The scientific literature about the role of PET-CT using FDG in the assessment of response to treatment with TKIs in patients affected by advanced RCC was systematically reviewed.

Results: Seven studies about the role of PET-CT using FDG in the response assessment after treatment with TKIs (essentially sunitinib and sorafenib) in advanced RCC were retrieved in full-text and analysed, to determine the predictive role of this morpho-functional imaging method on patient outcome.

Conclusions: To date, the role of PET-CT using FDG in evaluating the response to TKIs in metastatic RCC patients is still not well defined, partly due to heterogeneity of available studies; however, PET-CT reveals potential role for the selection of patients undergoing therapy with TKIs. The use of contrast-enhanced PET-CT appears to be promising for a "multi-dimensional" evaluation of treatment response in these patients.

Citing Articles

Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature.

Calderon L, Eismann L, Reese S, Reznik E, Hakimi A Cancers (Basel). 2023; 15(2).

PMID: 36672304 PMC: 9856305. DOI: 10.3390/cancers15020354.

Recent advances in imaging techniques of renal masses.

Aggarwal A, Das C, Sharma S World J Radiol. 2022; 14(6):137-150.

PMID: 35978979 PMC: 9258310. DOI: 10.4329/wjr.v14.i6.137.

Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [F]FDG PET/CT.

Ferrari C, Santo G, Ruta R, Lavelli V, Rubini D, Mammucci P Diagnostics (Basel). 2021; 11(8).

PMID: 34441351 PMC: 8392185. DOI: 10.3390/diagnostics11081417.

Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.

Jena R, Narain T, Singh U, Srivastava A Indian J Urol. 2021; 37(2):125-132.

PMID: 34103794 PMC: 8173953. DOI: 10.4103/iju.IJU_268_20.

Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?.

Pozzessere C, Bassanelli M, Ceribelli A, Rasul S, Li S, Prior J Curr Urol Rep. 2019; 20(11):68.

PMID: 31605269 DOI: 10.1007/s11934-019-0938-9.

References

Khandani A, Cowey C, Moore D, Gohil H, Rathmell W . Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun. 2012; 33(9):967-73. DOI: 10.1097/MNM.0b013e3283561837. View

Segota E, Mekhail T, Olencki T, Hutson T, Dreicer R, Wacker B . Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol. 2007; 25(1):46-52. DOI: 10.1016/j.urolonc.2006.02.016. View

Wang H, Ding H, Chen J, Chao C, Lu Y, Lin W . Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012; 12:464-74. PMC: 3483599. DOI: 10.1102/1470-7330.2012.0042. View

Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View

Whiting P, Weswood M, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J . Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006; 6:9. PMC: 1421422. DOI: 10.1186/1471-2288-6-9. View

Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A . Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group.... Br J Cancer. 2005; 92(5):843-6. PMC: 2361915. DOI: 10.1038/sj.bjc.6602443. View

Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just P . 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009; 24(1):137-44. DOI: 10.1089/cbr.2008.0527. View

Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View

Revheim M, Winge-Main A, Hagen G, Fjeld J, Fossa S, Lilleby W . Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2010; 23(5):339-43. DOI: 10.1016/j.clon.2010.11.006. View

10.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

11.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View

12.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L . Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011; 104(8):1256-61. PMC: 3078589. DOI: 10.1038/bjc.2011.103. View

13.

Vaishampayan U, Heilbrun L, Shields A, Lawhorn-Crews J, Baranowski K, Smith D . Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma. Invest New Drugs. 2006; 25(1):69-75. DOI: 10.1007/s10637-006-9005-8. View

14.

Jonasch E, Corn P, Pagliaro L, Warneke C, Johnson M, Tamboli P . Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2009; 116(1):57-65. PMC: 4636203. DOI: 10.1002/cncr.24685. View

15.

Eichelberg C, Heuer R, Chun F, Hinrichs K, Zacharias M, Huland H . Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008; 54(6):1373-8. DOI: 10.1016/j.eururo.2008.07.051. View

16.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

17.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A . Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011; 17(18):6021-8. DOI: 10.1158/1078-0432.CCR-10-3309. View

18.

Bukowski R . Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer. 2009; 115(10 Suppl):2273-81. DOI: 10.1002/cncr.24226. View

19.

Cella D, Michaelson M, Bushmakin A, Cappelleri J, Charbonneau C, Kim S . Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010; 102(4):658-64. PMC: 2837567. DOI: 10.1038/sj.bjc.6605552. View

20.

Weikert S, Ljungberg B . Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol. 2010; 28(3):247-52. DOI: 10.1007/s00345-010-0555-1. View